Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Learn about effective wealth building actions for this year that can enhance your savings and investment strategies for long-term success.
24,006 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Northcoast downgraded Norwegian Cruise Line amid macro headwinds, signaling tougher times for the sector as Middle Ea...
Do well carbon taxes match the promises policymakers make? This deep dive examines 2023 evidence, compares design cho...
Anthropic’s spacex compute deal expands access to the Colossus supercomputer, boosting Claude capacity while triggeri...
A rapid Trump-backed rally has pushed stocks to fresh highs, yet selective bargains remain. The market shows pockets ...
Public health headlines can knock your finances off balance. This article breaks down practical steps to protect savi...
Arm Holdings stunned markets with a powerful run, then pulled back after earnings. This guide breaks down whether thi...
As housing demand cools, Home Depot and Lowe’s diverge on dividend resilience. Home Depot shows stronger cash flow an...
A big jump in ezcorp stock 130% has investors buzzing. This piece explains what happened, why an investor sold millio...
GO Mortgage unveils a TPO channel built on a new wholesale platform, led by Rob Saunders, aiming to streamline origin...
This guide breaks down what to watch in allogene (allo) 2026 earnings. Learn how pipeline progress, cash runway, and ...
Trump’s move to bring Elon Musk into a China diplomacy frame marks a dramatic shift for investors. The pairing could ...